Search the Newsreel

Price to book forward of CalciMedica, Inc. – BOATS:CALC

The article provides a financial data point for CalciMedica, Inc. (CALC) related to its "Price to book forward" metric. It appears to be a stub or partial financial report from TradingView, indicating the company's market status and some basic financial information without further details …

CalciMedica Releases Q2 2026 Financial Results

CalciMedica (CALC) reported a wider net loss of $7.7M, or $0.45 per share, for Q2 2026, an increase from $0.40 per share in Q2 2025. This reflects continued investment in its biopharmaceutical pipeline and the capital-intensive nature of clinical-stage development. Despite the losses, analyst …

CalciMedica, Inc. 2Q 2026: Net loss $7.7M, EPS $(0.45) — 10-Q Summary

CalciMedica, Inc. reported a net loss of $7.7 million for the second quarter of 2026, an increase from the $6.0 million loss in the prior year, with diluted loss per share at $(0.45). The company's clinical development is focused on Auxora and CM5480, with …

CalciMedica Q2 FY26 net loss widens to $7.65 million

CalciMedica reported a widened net loss of $7.65 million for Q2 FY26, up from $5.96 million in the prior year, with loss per share increasing to $0.45. Despite this, the company saw a significant reduction in R&D and G&A expenses and increased its cash …

CalciMedica stock gains 6% despite earnings miss on pulmonary trial

CalciMedica (NASDAQ:CALC) reported a second-quarter loss of $0.45 per share, missing analyst estimates, yet its stock rose 6.22% in pre-market trading. The increase was driven by investor focus on the company's advances in its pulmonary hypertension program and regulatory progress, including FDA alignment for …

CalciMedica GAAP EPS of -$0.45 misses by $0.16

* CalciMedica press release [https://seekingalpha.com/pr/20614225-calcimedica-reports-second-quarter-2026-financial-results-and-provides-clinical-and-corporate] (CALC [https://seekingalpha.com/symbol/CALC]): Q2 GAAP EPS of -$0.45 misses by $0.16. * Cash Position: Cash and cash equivalents were $18.6 million as of June 30, 2026. The Company expects its cash and cash equivalents to fund its current operating plan …

CalciMedica Inc expected to post a loss of 28 cents a share - Earnings Preview

CalciMedica Inc is projected to report a loss of 28 cents per share, according to this earnings preview. The information was sourced from Refinitiv and distributed via Reuters. Readers can access the full article through TradingView.

CalciMedica Inc (CALC) Earnings Forecast: Future EPS & Revenue Growth Estimates

The article provides an earnings forecast for CalciMedica Inc (CALC), highlighting analyst ratings, target prices, and historical EPS performance. Analysts currently have a "Buy" consensus for CALC, with a target price of USD 15.50 and a significant upside potential of +1374.72%. The previous quarter's …

CalciMedica, Inc. SEC Filing (Aug 3, 2026)

This article reports on CalciMedica, Inc.'s SEC filing, specifically a Notice of Effectiveness for an S-3 form, dated July 31, 2026. The filing indicates a "Neutral" impact and sentiment according to AI analysis. The company's latest news and other recent SEC filings are also …

CalciMedica Inc (CALC:UR): Stock Price, Quote and News

This page from BNN Bloomberg provides information on CalciMedica Inc (CALC:UR), including its stock price, quote, and related news. It appears to be a company-specific page on a financial news platform, offering resources for investors to track the company's performance and developments. The content …

CalciMedica Inc (CALC) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of CalciMedica Inc (CALC), detailing its support, resistance levels, and various technical indicators. It includes a summary of "Sell," "Neutral," and "Buy" signals based on indicators like MACD, RSI, and moving averages. The analysis suggests a "Neutral" signal …

CalciMedica Announces FDA Alignment on Phase 2b Trial Design for Auxora in Acute Pancreatitis and Identifies Disease's First Potential Registrational Endpoints

CalciMedica announced FDA alignment on the Phase 2b trial design for Auxora in acute pancreatitis (AP), identifying new-onset severe respiratory failure as the primary endpoint. The FDA also agreed on evaluating elevated lactate dehydrogenase (LDH) as a potential biomarker to identify high-risk patients. This …

CalciMedica Inc (CALC) Financial Health: Profitability & Balance Sheet Analysis

This article provides a financial health overview of CalciMedica Inc (CALC), focusing on its profitability and balance sheet analysis. As of the close on July 27, 2026, the company's stock was trading at $0.708, experiencing a 6.78% drop. The content highlights key financial data …

CalciMedica Inc (CALC) Institutional Confidence

This article provides details on the institutional confidence in CalciMedica Inc (CALC), listing key shareholders and their respective shareholdings. The data includes the number of shares held by entities like Sanderling Ventures and Alafi Capital Company, as well as changes in their holdings. The …

CalciMedica Inc (CALC) Cash Flow

This article provides a detailed cash flow statement for CalciMedica Inc (CALC), including operating, investing, and financing cash flows presented quarterly. It highlights key financial figures such as net income from continuing operations, capital expenditures, and free cash flow for various fiscal quarters. The …

CalciMedica, Inc. Revenue Breakdown – NASDAQ:CALC

This article provides a basic overview of CalciMedica, Inc. (NASDAQ:CALC) financials, specifically referencing its revenue breakdown section on TradingView. It indicates that the company's financial data, including segments and regional performance, is available for review, though the specific breakdown content is not included in …

TradingKey

This article provides a detailed financial overview of CalciMedica Inc (CALC), focusing on its quarterly and annual income statements. It presents a comprehensive table of income statement metrics from FY2020Q3 to FY2026Q1, including operating expenses, R&D expenses, operating profit, net income, and EPS. The …

CALC|CalciMedica Inc|Price:0.721|Chg%:-0.039

CalciMedica Inc. (CALC) is a clinical-stage biopharmaceutical company focused on developing therapies for inflammatory and immunologic diseases by inhibiting CRAC channels. Their lead product candidate, Auxora, is in Phase IIb trials for acute pancreatitis and supporting Phase I/II studies for asparaginase-induced pancreatic toxicity. The …

CalciMedica Inc (CALC) Shareholder Structure: Major Shareholders & Institutional Holdings

This article provides an overview of CalciMedica Inc.'s (CALC) shareholder structure, detailing major shareholders and institutional holdings. It lists the top individual and venture capital firms holding significant proportions of shares, along with statistics on institutional ownership over several quarters. The data includes the …

CalciMedica (NASDAQ: CALC) files to register 56M shares from June 2026 PIPE

CalciMedica (NASDAQ: CALC) has filed a resale registration statement (S-3) for up to 56,020,287 shares of common stock. These shares are intended for resale by selling stockholders and include shares issued in a June 23, 2026 private placement, as well as shares issuable upon …

CalciMedica (NASDAQ: CALC) plans reverse split, 7.5M-share equity plan boost and warrant votes

CalciMedica (NASDAQ: CALC) is seeking stockholder approval for a reverse stock split at a ratio between 1-for-2 and 1-for-10, an increase of 7.5 million shares to its 2023 Equity Incentive Plan, and the approval of warrant issuances related to a recent private placement. These …

Price to earnings forward of CalciMedica, Inc. – NASDAQ:CALC

The article displays the "Price to earnings forward" metric for CalciMedica, Inc. (NASDAQ: CALC) on the TradingView platform. It shows that the value is currently not available, indicating a focus on financial data for this specific company.

CalciMedica (CALC): CVI Investments and Heights Capital disclose 5.1% equity stake

CVI Investments, Inc. and Heights Capital Management, Inc. have disclosed a beneficial ownership of 1,556,081 shares of CalciMedica (CALC) common stock, representing a 5.1% equity stake. This information was reported in a Schedule 13G SEC filing. Heights Capital Management acts as the investment manager …

CalciMedica (CALC) price target decreased by 24.39% to 10.54

This article reports that the price target for CalciMedica (CALC) has been decreased by 24.39%, settling at $10.54. No further details were provided regarding the reasons for this adjustment.

CalciMedica Reports 2025 Financial Results and Provides Clinical Updates

CALCIMEDICA (CALC) Stock Price, News & Analysis

CalciMedica Inc (CALC:UQ): Stock Price, Quote and News

CalciMedica (CALC) Stock Price, News & Analysis $CALC